Asthma Inflammation Research
Overview
- Phase
- Early Phase 1
- Intervention
- Nutritional approach for asthma
- Conditions
- Asthma
- Sponsor
- The Cleveland Clinic
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Maintaining a tolerance to Medium Chain Triglyceride (MCT) additive for Asthmatics
- Status
- Enrolling By Invitation
- Last Updated
- 10 months ago
Overview
Brief Summary
The overall goal of the Asthma Inflammation Research [AIR] Translational Program is to create an integrated multidisciplinary team for the focused purpose of development of diagnostic and prognostic tests informative for airway inflammation, and for the design of innovative, targeted biologic therapeutics.
The overarching aims of the AIR program are to conceptualize, develop, and test the next-generation therapeutics, and novel asthma diagnostic and prognostic tools that will allow us to improve the standard of asthma care.
Detailed Description
More than 20 million Americans suffer from asthma, and nearly half of asthma sufferers do not have their asthma under control. Although commonly diagnosed using physiological measures of airflow and bronchial hyperreactivity, asthma pathophysiology is related to chronic inflammation of the airway. Current diagnostic evaluation and monitoring are inadequate for proposed practice guidelines. The most commonly used test for evaluation of asthma is the measurement of airflow obstruction by spirometry. The National Asthma Education Prevention Program (NAEPP) and Expert Panel Reports set forth grading of asthma severity based on the frequency of symptoms, airflow, and the need for inhaled beta-agonists. Practice guidelines outline that the goals of therapy for asthma are to: maintain normal activity with near normal parameters of lung function, prevent exacerbations that lead to tissue injury, and avoid medication toxicity. In order to facilitate these goals, NAEPP defines key components for management including disease monitoring and stepped care pharmacotherapy. Unfortunately, there is no optimal plan for monitoring inflammation, which causes us to fail in key components in management of asthma. Limited options for anti-inflammatory treatments to control asthma likewise often lead to substantial morbidities due to treatment with high doses of corticosteroids. Our AIR program plans to develop novel asthma monitoring tests and design targeted therapeutics, which altogether may reduce toxicities and improve the long-term health of patients. Impact on broad scientific advancement. Our cumulative studies provide fundamental information on the molecular mechanisms that contribute to unresolving and excessive inflammation that leads to tissue remodeling. This mechanistic knowledge is of broad scientific importance as nearly all chronic human diseases are defined by prolonged and active inflammation, with tissue destruction, and failed attempts at healing. Thus, our investigations will provide comprehensive knowledge and consequent translational deliverables that may be widely applicable as diagnostic strategies and therapies in other chronic inflammatory diseases.
Investigators
Serpil Erzurum
Chair of Lerner Research Institute
The Cleveland Clinic
Eligibility Criteria
Inclusion Criteria
- •Asthma diagnosed by a medical specialist and/or history of positive methacholine rest and/or reversibility of \>10% of FEV1
- •FEV1 is within acceptable limits
- •Informed Consent is present
Exclusion Criteria
- •Diabetes (fasting blood sugar \>110 mg/dL)
- •Any milk allergies
- •Coconut allergies
- •BMI \>40 kg/m2,
- •Inability to maintain diet intervention
- •Current smoking or smoking history of greater than 10 pack-years
- •Any other significant respiratory or cardiac disease or the presence of clinically important comorbidities, including, uncontrolled coronary artery disease, acute or and chronic renal failure
Arms & Interventions
Nutritional Approach for Asthma
individuals will be provide a pre measured dose of medium chain triglyceride to consume along with their meals. They will be instructed to add the MCT to their meal 3 times per day
Intervention: Nutritional approach for asthma
Standard American Diet
patients will consume their usual diet with a pre measured dose of canola oil in place of the medium chain triglyceride as a control group. They will be instructed to add the placebo dose to their meal 3 times a day
Intervention: Nutritional approach for asthma
Alternate Day Diet
patients will consume a regular "Standard American Diet" for 4 weeks and then provided a regulated dosed quantity of low caloric value "shakes". they will consume this on alternating days
Intervention: Low Caloric Shake
Whole Lung Allergen Challenge
patients with or without asthma will be given controlled doses of specified allergens
Intervention: whole lung allergen challenge
Outcomes
Primary Outcomes
Maintaining a tolerance to Medium Chain Triglyceride (MCT) additive for Asthmatics
Time Frame: 24 weeks
Tolerability of the MCT will be assessed by maintenance of use of MCT by 20% or more participants over the 3 months of the study.
Secondary Outcomes
- Gastrointestinal tolerance of a Medium Chain Triglyceride additive to a normal diet in Asthmatics(12)
- Improvement of lung function by spirometry testing(24 weeks)
- Asthma Quality of Life Questionnaire(24 weeks)
- Asthma Control Test(24 weeks)